SLC5A2 and Glycosuria: In fact, inT2DM patients, sotagliflozin-induced glucosuria was comparable tothat of more selective SGLT-2 inhibitors; moreover, once it reacheda plateau (UGE about 60 g/24 h with 200 mg daily dose), UGE valuesno longer increased by successive dose increments.